Ellen J. Hulskotte
Oss, NB, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Journal: Journal of clinical pharmacology
Published: October 17, 2017
Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.
Journal: British journal of clinical pharmacology
Published: May 25, 2016
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
Journal: Clinical pharmacokinetics
Published: March 20, 2015
Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.
Journal: European journal of clinical pharmacology
Published: July 10, 2014
Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
Journal: Vaccine
Published: January 22, 2014
Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Journal: Antimicrobial agents and chemotherapy
Published: March 27, 2013
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 17, 2012
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Journal: Hepatology (Baltimore, Md.)
Published: February 07, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026